Your browser doesn't support javascript.
loading
Overview of Ocular Side Effects of Selinexor.
Al-Zubidi, Nagham; Gombos, Dan S; Hong, David S; Subbiah, Vivek; Fu, Siqing; Ahnert, Jordi Rodon; Piha-Paul, Sarina A; Tsimberidou, Apostolia M; Karp, Daniel D; Bernstam, Funda Meric; Naing, Aung.
Afiliación
  • Al-Zubidi N; Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gombos DS; Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hong DS; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Fu S; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ahnert JR; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Karp DD; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Bernstam FM; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Naing A; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oncologist ; 26(7): 619-623, 2021 07.
Article en En | MEDLINE | ID: mdl-33728727
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Hidrazinas Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Oncologist Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Hidrazinas Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Oncologist Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos